Orbimed Advisors LLC Jounce Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $193,200 - $529,230	69,000 Added 2.41%	2,928,900 $8.88 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $1.45 Million - $1.97 Million	204,300 Added 7.69%	2,859,900 $23.9 Million
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $2.56 Million - $4.44 Million	508,200 Added 23.67%	2,655,600 $19.7 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $2.13 Million - $3.45 Million	323,800 Added 17.76%	2,147,400 $14.6 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $12.3 Million - $25.3 Million	1,823,600 New	1,823,600 $18.7 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.